Preclinical models of natural killer cell-based immunotherapy to cure refractory childhood acute lymphoblastic leukemia
Preclinical models of natural killer cell-based immunotherapy to cure refractory childhood acute lymphoblastic leukemia
批准号:
279959
负责人:
Duval Michel
金额:
$24.18万
依托单位国家:
加拿大
项目类别:
Operating Grants
财政年份:
2013
资助国家:
加拿大
项目状态:
已结题
起止时间:
2013-03-01 至 2016-03-01
中文摘要
点击翻译按钮获取中文摘要
英文摘要
Forty to fifty percent of children whose leukemia reappears following treatment die of their disease, underscoring an urgent need to improve current therapies. The only hope of a cure for these children is intensive highly toxic chemotherapy followed by t
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Phase I first-in-human trial for ThINKK adoptive immunotherapy in children with high-risk cancers
-
批准号:484371
-
项目类别:Operating Grants
-
资助金额:$7.29万
-
财政年份:2023
-
负责人:Duval Michel
-
依托单位:
Phase I first-in-human trial of ThINKK adoptive immunotherapy in children with high-risk cancers
-
批准号:473376
-
项目类别:Operating Grants
-
资助金额:$7.29万
-
财政年份:2022
-
负责人:Duval Michel
-
依托单位:
Adoptive transfers of in vitro differentiated plasmacytoid dendritic cells to prevent acute lymphoblastic leukemia relapse: mechanisms and biomarkers of sensitivity
-
批准号:402466
-
项目类别:Operating Grants
-
资助金额:$49.04万
-
财政年份:2019
-
负责人:Duval Michel
-
依托单位:
Toward the cure of neuroblastoma: innovative immunotherapeutic approaches
-
批准号:322744
-
项目类别:Operating Grants
-
资助金额:$72.63万
-
财政年份:2015
-
负责人:Duval Michel
-
依托单位:
海外基金